The maker of Ozempic and Wegovy just made a bet that AI could help it find the next big weight loss drug faster. Novo Nordisk said Tuesday it's teaming up with OpenAI to bring AI into its drug work. The goal is to crunch huge data sets, spot trends that human teams might miss, and shave time off how long it takes to get new drugs to market. Novo stock rose about 3% on the news.
Novo's CEO Mike Doustdar said the deal will let the firm "analyze data sets at a scale that was not possible before." OpenAI's Sam Altman said AI "can help people live better, longer lives."
This isn't Novo's first AI move. The firm already works with Nvidia on a super fast computer for drug research. The OpenAI deal adds a new layer. It uses large language models - the same tech behind ChatGPT - to read through trial data and help design better studies. In plain terms: Think of it like having a very smart helper that can read millions of pages of medical data in seconds and flag the parts that matter most. Humans still make the calls. But the AI does the grunt work much faster.
Here's the honest truth. AI in drug research is still in its early days. Most of the gains so far come from small wins - finding the right patients for a trial faster, cutting down paperwork, or flagging safety issues earlier. The big dream - using AI to find a brand new drug from scratch - is not there yet. But even small time savings matter when billions of dollars are on the line. Why speed matters so much: Getting a drug to market six months sooner could mean billions in extra sales. In the weight loss space, where demand is through the roof, every month counts.
Novo had a head start in the weight loss drug market. But Eli Lilly has been closing the gap fast with its rival drug Zepbound. Novo launched a Wegovy pill in January. It's also working on next-gen drugs that could work better and cost less. If AI helps Novo move faster on those, it could win back the ground it lost. The stakes are massive. The global market for weight loss drugs could top $100 billion a year by the end of the decade. Whoever gets there first with the best drug wins.
The test isn't whether Novo uses AI. Every big drug firm is doing that now. The test is whether AI makes the process faster and gets new drugs to patients sooner. That proof could take years. But investors are betting on it now.
The race between Novo and Lilly is one of the biggest in all of health care. Both firms are worth hundreds of billions. Both have drugs that sell out almost as fast as they can make them.
Any edge - even a small one - could be worth tens of billions in sales. That's why the market cares so much about a deal with a tech firm. It's not about AI for the sake of AI. It's about who finds the next drug first. Tuesday's 3% stock jump shows that investors like the odds. But the real payoff is years away. This is a long game.
